The information highlighted (if any) are the most recent updates for this brand.
When 100 to 330 times of the recommended clinical dose (30 to 100 mg/kg/day) of Mosapride citrate was orally administered in rodents for long period (104 weeks in rats, 92 weeks in mice), increased incidence of hepatocellular adenoma and thyroid follicular cell adenoma were observed.